This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Rebecca Voelker

JAMA. 2000;283:1557.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A new policy report from the American Urological Association (AUA) advises physicians on the best use of prostate-specific antigen (PSA) testing in the diagnosis and management of prostate cancer.

"The report cuts to the quick of what we actually know about the PSA test, thereby helping to eliminate many commonly performed procedures used to diagnose, stage, and monitor prostate cancer," said Ian Thompson, MD, of the University of Texas, San Antonio, Medical Center, and chair of the AUA committee that developed the policy.

According to the report, physicians should consider performing a biopsy to confirm a diagnosis of prostate cancer if the PSA level is 4.0 ng/mL or higher, if a patient's PSA level increases significantly from one test to the next, or if a digital rectal examination (DRE) is abnormal. "PSA currently is the best single test for early prostate cancer detection, but the combination of PSA . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?